期刊
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
卷 60, 期 10, 页码 6407-6410出版社
AMER SOC MICROBIOLOGY
DOI: 10.1128/AAC.01282-16
关键词
-
资金
- AstraZeneca Pharmaceutical Spain
- Ministerio de Ciencia e Innovacion of Spain, Instituto de Salud Carlos III through the Spanish Network for Research in Infectious Diseases [REIPI RD12/0015, RD16/00016]
- European Regional Development Fund A Way To Achieve Europe ERDF
The activity of ceftazidime-avibactam was compared with that of ceftazidime alone and meropenem against a collection of 190 Pseudomonas aeruginosa clinical isolates recovered from a multicenter study of bloodstream infections. The addition of avibactam increased ceftazidime susceptibility in the complete collection of strains (64.7% to 91.1%) and particularly among subsets of isolates showing AmpC hyperproduction (10.9% to 76.1%) or multidrug resistance (MDR) profiles (27% to 77.8%). The MICs of ceftazidime-avibactam, in contrast with those of ceftazidime or meropenem, remained at <= 4 mu g/ ml for a panel of 16 P. aeruginosa PAO1 isogenic mutants expressing multiple combinations of the most relevant beta-lactam resistance mechanisms.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据